Marine peptides and nucleotides

Patent metadata

Field	Value
Publication number	US-10213473-B2
Application number	US-201515329953-A
Country	US
Kind code	B2
Filing date	Jul 30, 2015
Priority date	Jul 31, 2014
Publication date	Feb 26, 2019
Grant date	Feb 26, 2019

Abstract

Provided herein is a method of reducing postprandial concentrations of glucose in a subject's blood comprising administering to the subject, prior to or during a meal, an effective amount of a combination of a marine peptide and a fish nucleotide, sufficient to reduce the glucose concentration in the subject's blood. Further provided herein is a method of reducing postprandial concentration of ghrelin in a subject's blood, comprising administering to the subject, prior to or during a meal, an effective amount of a combination of a marine peptide and a fish nucleotide sufficient to increase the blood component wherein the combination is administered to the subject.

First claim

The invention claimed is:

1. A method of reducing postprandial concentrations of glucose in a subject's blood comprising administering to the subject an effective amount of a combination of marine peptides and fish nucleotides sufficient to reduce the glucose concentration in the subject's blood, wherein the combination is administered to the subject prior to or during a meal; wherein the marine peptides and the fish nucleotides are present in a ratio of about 2:1 to about 10:1 by weight of the total weight of the combination; wherein the marine peptides are obtained by enzymatic hydrolysis of at least one marine protein and have a molecular weight in the range of from 1 to 20,000 Da; and wherein the fish nucleotides are extracted from tissue of fish, marine algae, crustaceans or shellfish and have less than 2% proteins comprising essentially of pure DNA or fragments thereof.

2. The method as recited in claim 1 wherein the subject is a human.

3. The method as recited in claim 1 wherein the subject is in need of such reduction.

4. The method as recited in claim 1 wherein the marine peptide is provided in an amount of about 5 mg to about 50 mg per 1 Kg bodyweight of the subject.

5. The method as recited in claim 4 wherein the marine peptide is provided in an amount of about 20 mg per Kg bodyweight of the subject.

6. The method as recited in claim 1 wherein the combination is administered to the subject for a period of time sufficient to reduce the subject's insulin resistance.

7. The method as recited in claim 1 wherein the combination is administered to a subject having an HbA1C level equal to or greater than 6 for a period of time to reduce the HbA1C level.

8. The method as recited in claim 7 wherein the HbA1C level is greater than 6.5.

9. The method as recited in claim 8 wherein the HbA1C level is greater than 7.

10. The method as recited according to claim 1 wherein the combination is provided as a fixed dietary for the management of glucose levels in the subject.

11. The method as recited according to claim 1 wherein the combination is provided as a pharmaceutical preparation for the treatment of a condition selected from the group consisting of pre-diabetes or diabetes.

12. The method as recited in claim 1 wherein the combination is provided in a dietary supplement for the maintenance of blood sugar health.

13. The method as recited in claim 1 wherein the fish nucleotide is provided in an amount equal to about 25% of the weight of the marine peptide.

14. A composition comprising a combination of isolated marine peptides and isolated fish nucleotides in a ratio of about 10:1 by weight of the total weight of the combination wherein the combination is provided in an amount effective to reduce blood levels of glucose in a subject; wherein the marine peptides are obtained by enzymatic hydrolysis of at least one marine protein and have a molecular weight in the range of from 1 to 20,000 Da; and wherein the fish nucleotides are extracted from tissue of fish, marine algae, crustaceans or shellfish and have less than 2% proteins comprising essentially of pure DNA or fragments thereof.

Assignees

• Firmenich & Cie

Inventors

• Lied Einar
• Bjorge Oddvar

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title